Oxytocin Market Size was valued at USD 0.08 Billion in 2022. The oxytocin market industry is projected to grow from USD 0.088 Billion in 2023 to USD 0.178 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.20% during the forecast period (2023 - 2032). The rising incidence of pregnancy problems, the rise in births worldwide, and the expanding public awareness of induced labor and breastfeeding are the factors propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Since oxytocin is frequently used to treat delivery difficulties, the number of cases of these complications has been rising over time and is expected to do so in the years to come. As a result, the market for this medication is expected to rise over the forecast period. According to the Blue Cross Blue Shield Association, women who experience difficulties throughout pregnancy are twice as likely to experience difficulties during childbirth. According to the June 2020 publication "Trends in Pregnancy and Childbirth Complications in the U.S.", between 2014 and 2018, there was a 16.4% increase in pregnancy difficulties and a 14.2% increase in birthing complications. The Blue Cross Blue Shield Association reports that eclampsia was the birthing complication that experienced the greatest growth between 2014 and 2018. In the United States, the prevalence rate of eclampsia grew by 57.9% between 2014 and 2018, rising from 1.1 cases per 1,000 to 1.7 cases per 1,000. The frequency of other problems has also been rising, including cardiomyopathy, embolism, sepsis, and respiratory distress. Oxytocin is becoming more and more necessary to start labor, intensify uterine contractions, and manage postpartum hemorrhage as a result of the rising number of difficulties associated with childbirth. Throughout the projected period, the rising trend of birth abnormalities is anticipated to support the oxytocin market's expansion.
Market expansion is facilitated by cooperative ventures and advancements related to oxytocin. Tonix Pharmaceuticals and Katana Pharmaceuticals, for instance, have a licensing agreement for Tonix's intranasal potentiated oxytocin, per the January 2021 update. In particular, insulin resistance, diabetes, and obesity will see a rise in the use of drugs to treat metabolic disorders. The principal indication for Tonix is migraine, although preclinical results also demonstrate the effectiveness of the intranasal oxytocin product TNX-1900 in disorders of the central nervous system. In June 2020, the company initially purchased oxytocin-potentiated therapy from Trigemina; this arrangement adds to that acquisition. Joint ventures and partnerships connected to oxytocin provide several indications and support the growth of the oxytocin market throughout the projected timeframe. Thus, driving the oxytocin market revenue.
The Oxytocin Market segmentation, based on product includes Antepartum and Postpartum. The postpartum segment dominated the market. Because postpartum oxytocin products have been shown to reduce postpartum hemorrhage, their use and applications are becoming more widely accepted worldwide as a means of reducing mother mortality.
Figure 1: Oxytocin Market, by Product, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Oxytocin Market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies. The hospital pharmacies category generated the most income. The bulk of oxytocin-related treatments are carried out in hospitals. Hospital networks also support the market for Oxytocin by increasing purchasing power, which makes them a significant Distribution Channel category.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American oxytocin market area will dominate this market. Growing national spending on personal care goods and rising awareness of pregnancy products are the main factors driving this market's expansion. An important component of the American healthcare system, maternal and child health has emerged as a result of the increased responsiveness, which has led to the success of initiatives aimed at raising public awareness about pregnancy.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: OXYTOCIN MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe oxytocin market accounts for the second-largest market share. Throughout the projection period, Germany is anticipated to be a profitable center for oxytocin product research, development, and manufacture in the European Union due to the presence of major industry players like Novartis that have a significant research impact on the entire market structure. Further, the German oxytocin market held the largest market share, and the UK oxytocin market was the fastest growing market in the European region
The Asia-Pacific Oxytocin Market is expected to grow at the fastest CAGR from 2023 to 2032 owing to a number of variables, including growing disposable income in developing nations like China and India, an expansion of established distribution networks, and increased consumer awareness of oxytocin products as a result of forceful advertising initiatives by significant players. Moreover, China’s oxytocin market held the largest market share, and the Indian oxytocin market was the fastest growing market in the Asia-Pacific region.
Oxytocin Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the oxytocin market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, oxytocin industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global oxytocin industry to benefit clients and increase the market sector. In recent years, the oxytocin industry has offered some of the most significant advantages to medicine. Major players in the oxytocin market are attempting to increase market demand by investing in research and development operations includes Pfizer Inc., Fresenius Kabi LLC, Endo International plc. (Par Sterile Products, LLC), Wockhardt Ltd., Novartis AG, Ferring B.V., Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Yuhan Corporation.
Fresenius Kabi USA LLC (also known as Fresenius Kabi), a division of Fresenius Kabi AG, is a pharmaceutical and medical equipment manufacturer offering technologies and medications for clinical nutrition, transfusion, and infusion. It offers goods and services to those who are seriously and persistently unwell. The company provides sophisticated transfusion medicine, infusion, cell therapy, injectable medications, and clinical nutrition technology. Oncology, anesthesia, analgesia, parenteral nutrition, IV solutions, anti-infectives, and other critical care medicines are among its offerings.
Hikma Pharmaceuticals Plc (Hikma) creates, produces, and sells in-licensed goods as well as branded and non-branded generics. Cardiovascular disease, diabetes, cancer, the central nervous system (CNS), dermatology, the genitourinary system, hormones, and the respiratory system are among the specialties of the company. It provides generics in a range of dosage forms, including as tablets, capsules, liquids, and suspensions. Hikma Pharmaceuticals distributes its goods to top wholesalers, pharmacy chains, governments, and hospital buying organizations through sales and marketing teams and representatives.
Key Companies in the oxytocin market include
Oxytocin Industry Developments
August 2022:The US patent for the painkiller intranasal oxytocin (TNX-1900) was awarded to Tonix Pharmaceuticals. Under the heading "Magnesium-Containing Oxytocin Formulations and Methods of Use," the patent sought to protect patients from pain—including migraine headaches—by employing intranasal formulations of oxytocin that contain magnesium. Tonix should have U.S. market exclusivity through January 2036 thanks to this invention, barring any potential patent term extensions.
May 2020:Carbetocin Ferring, a heat-stable formulation approved by Swissmedic, is used to prevent postpartum hemorrhage in all births. This drug is the first to be approved under the new MAGHP (Marketing Authorization for Global Health Products) and Swissmedic procedures.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.08 Billion |
| Market Size 2023 | USD 0.088 Billion |
| Market Size 2032 | USD 0.178 Billion |
| Compound Annual Growth Rate (CAGR) | 9.20% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer Inc., Fresenius Kabi LLC, Endo International plc. (Par Sterile Products, LLC), Wockhardt Ltd., Novartis AG, Ferring B.V., Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Yuhan Corporation |
| Key Market Opportunities | · Improvements to the Drug Delivery System |
| Key Market Dynamics | · Growing Concerns about Maternal Healthcare · Growing Number of Mental Health Conditions |
Frequently Asked Questions (FAQ) :
The Oxytocin Market size was valued at USD 0.08 Billion in 2022.
The global market is projected to grow at a CAGR of 9.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Pfizer Inc., Fresenius Kabi LLC, Endo International plc. (Par Sterile Products, LLC), Wockhardt Ltd., Novartis AG, Ferring B.V., Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Yuhan Corporation.
The postpartum category dominated the market in 2022.
The hospital pharmacies category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
